Any Amazon users? Please help us raise money to allow this project (mentioned below) to continue. It is the most important project we ever funded and is making a huge difference in kids and young adult lives right now, and will hopefully speed up approval of the drug so that all those who need it can get it.
Disclaimer: This grant is venture philanthropy - which means if it is successful, the Musella Foundation will get a return.
First-line treatment of ONC 201 in newly diagnosed DIPG pediatric patients is now open. There are a few trials of this drug, as well as the compassionate use program, but a new trial opened that requires DIPG patients to start before radiation. It is hard to get the word out to those patients since things happen so fast when first diagnosed and most families are in shock. So if you hear of a patient diagnosed with DIPG, mention this trial to them as an option.
Disclaimer: The Musella Foundation gave a venture philanthropy grant to the company that makes Onc-201 - which means the foundation gets a return if the drug is successful.
Oncology Pioneer xCures Names Experts to Advisory Boards We are partnering with this company (and Cancer Commons) to track the patients in our Onc-201 compassionate use program. We are testing a program that will allow our patients to utilize xCures' services at no cost to the patients or to the Musella Foundation. xCures will evaluate a patient’s case, figure out the best treatment options using a combination of artificial intelligence, nurse navigators, research scientists, internal tumor board and an external virtual tumor board. xCures will then present the options to the patient who then decides with their own medical team which option to pursue. xCures will then help them get access to the treatments if needed, and then follow up to see how it works out, both to add knowledge to their knowledge base and to help again if there is a recurrence.
Disclaimer: I am a paid consultant for this company and I am an investor.
